Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Mucinous breast carcinoma, a rare and unique subtype of breast cancer, has long been a focus of intense research. At Alfa Cytology, our team of experienced biologists work with you to develop therapeutics for mucinous breast carcinoma.
Accounting for approximately 2% of all breast cancer cases, mucinous carcinoma is characterized by the presence of abundant extracellular mucin production, which sets it apart from the more common infiltrating ductal carcinoma. At the molecular level, mucinous breast carcinoma are predominantly of the luminal A intrinsic subtype, exhibiting low levels of genetic instability and rare recurrent amplifications. This unique genomic landscape offers both challenges and opportunities in the pursuit of more effective therapeutic strategies.
Fig.1 Histopathological image of pure mucinous breast cancer (PMBC) (grade 2, H&E)-characteristic cancer cells "nests" foating in abundant extracellular mucus. (Budzik M.P., et al. 2021)
Researchers are exploring a variety of combination approaches, including standard chemotherapies as well as targeted agents like RANKL inhibitors, to improve outcomes for patients with mucinous breast carcinoma. The use of nanoparticle-based delivery of paclitaxel is also being investigated.
| Category | Therapeutics | Phase | NCT |
| Combination Therapies | Paclitaxel, Cisplatin | NCT03201861 | |
| Paclitaxel + Cisplatin + Gonadotropin-releasing hormone agonist | NCT02221999 | ||
| Neoadjuvant Chemotherapy | RANKL Inhibitor | NCT02682693 | |
| Nanoparticle-based Therapy | nab-Paclitaxel | NCT01583426 |
Mucinous breast carcinoma is a relatively rare disease but malignant. Multiple factors influence prognosis and therapy options. Therefore, Alfa Cytology is working on providing one-stop solutions for mucinous breast carcinoma, including but not limited to the following.
Therapy Development
At Alfa Cytology, our comprehensive suite of oncology services and deep disease-specific expertise provide a powerful platform for accelerating the development of novel mucinous breast carcinoma therapies. From molecular profiling and biomarker discovery to the establishment of robust preclinical models and the systematic evaluation of therapeutic candidates, our team of cancer experts is well-equipped to support researchers and clinicians at every stage of the drug development process. If you are interested in our service, please contact us.
Reference
